Anti-PCSK9 antibodies
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsMark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas MacDonald
Life of this patent
Estimating the term…
Abstract
An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
Claims18
An antibody or antigen-binding fragment of an antibody that specifically binds hPCSK9, comprising:
- a) a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:
- 76;
- b) a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:
- 78;
- c) a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:
- 80;
- d) a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:
- 84;
- e) a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:
- 86;
- and
- f) a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:
- 88.
An antibody or antigen-binding fragment of an antibody that specifically binds hPCSK9, comprising a heavy chain variable region comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:90;
- and a light chain variable region comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:92.
An antibody or antigen-binding fragment of an antibody that specifically binds hPCSK9, comprising:
- a) a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:
- 76;
- b) a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:
- 78;
- c) a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:
- 80;
- d) a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:
- 84;
- e) a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:
- 86;
- and
- f) a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:
- 88.
An antibody or antigen-binding fragment of an antibody that specifically binds hPCSK9, comprising a heavy chain variable region comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:90;
- and a light chain variable region comprising an amino acid sequence that is at least 98% identical to SEQ ID NO:92.
An antibody or antigen-binding fragment of an antibody that specifically binds hPCSK9, comprising:
- a) a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence that is at least 99% identical to SEQ ID NO:
- 76;
- b) a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence that is at least 99% identical to SEQ ID NO:
- 78;
- c) a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence that is at least 99% identical to SEQ ID NO:
- 80;
- d) a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence that is at least 99% identical to SEQ ID NO:
- 84;
- e) a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence that is at least 99% identical to SEQ ID NO:
- 86;
- and
- f) a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence that is at least 99% identical to SEQ ID NO:
- 88.
An antibody or antigen-binding fragment of an antibody that specifically binds hPCSK9, comprising a heavy chain variable region comprising an amino acid sequence that is at least 99% identical to SEQ ID NO:90;
- and a light chain variable region comprising an amino acid sequence that is at least 99% identical to SEQ ID NO:92.
Dependencies are inferred from the claim text.